比優集團(08053.HK)與鄂爾多斯市北安訂立新框架協議
格隆匯1月20日丨比優集團(08053.HK)發佈公告,2020年1月20日,鄂爾多斯市北安(作為客户)與盛安化工(鄂托克旗)及巴彥淖爾盛安(作為供應商)就出售粉狀乳化炸藥、銨油炸藥及膠狀乳化炸藥的持續關連交易訂立新框架協議。
公告表示,集團主要從事大宗礦產貿易、生產及銷售爆炸物品及提供爆破作業和相關服務。鄂爾多斯市北安主要在內蒙古鄂爾多斯市從事供應民用爆炸器材及材料的業務。盛安化工(鄂托克旗)與巴彥淖爾盛安皆為集團附屬公司,主要從事製造及銷售民用炸藥業務。通過訂立新框架協議,集團將在延長年期內具備充足空間應付持續關連交易的增長,以及延續訂約各方之間的長期業務關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.